Takeichi, TakayukiOhya, YukiInomata, YukihiroLee, Kwang-JongOkumura, KenjiYamamoto, HidekazuAsonuma, Katsuhiro2026-05-072013-04Experimental and Clinical Transplantation, Cilt, 11, Sayı, 2, 2013 ss. 182-1851304-0855https://hdl.handle.net/11727/15016Familial amyloid polyneuropathy is a rare, progressively disabling, and ultimately fatal inherited disease. Liver transplant is currently the only available treatment proven to halt the progression of familial amyloid polyneuropathy. We report a 31-year-old woman with familial amyloid polyneuropathy who received a living-donor liver transplant from her husband who was hepatitis C virus antibody-positive but HCV-RNA negative and ABO incompatible. Six years after the transplant, both donor and recipient have normal liver biochemistry results; no hepatitis C viral load has been detectable in the recipient. This is the first report of a living ABO-incompatible liver transplant from an anti-hepatitis C virus antibody-positive but an HCV-RNA negative donor. This experience suggests that the use of an anti-hepatitis C virus antibody-positive hepatic graft is possible in select circumstances.enFamilial amyloid polyneuropathyHepatitis C virusLiving-donor liver transplantABO-incompatible transplantCase Report1122146-8427